Postischemic sevoflurane offers no additional neuroprotective benefit to preischemic dexmedetomidine. [electronic resource]
Producer: 20130826Description: 184-90 p. digitalISSN:- 1537-1921
- Actins -- metabolism
- Anesthetics, Inhalation -- therapeutic use
- Animals
- Apoptosis Regulatory Proteins -- metabolism
- Blotting, Western
- Brain -- pathology
- Dexmedetomidine -- therapeutic use
- Hemoglobins -- metabolism
- Hypnotics and Sedatives -- therapeutic use
- In Situ Nick-End Labeling
- Ischemic Attack, Transient -- pathology
- Ischemic Preconditioning -- methods
- Methyl Ethers -- therapeutic use
- Neuroprotective Agents
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Rats
- Rats, Sprague-Dawley
- Reperfusion Injury -- prevention & control
- Sevoflurane
- Tissue Embedding
- bcl-2-Associated X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.